Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1

Publication date: 17 April 2018
Source:Immunity, Volume 48, Issue 4
Author(s): Melissa A. Meyer, David G. DeNardo
T cell checkpoint blockades can produce durable clinical responses, but only some patients and cancer types respond. In this issue of Immunity, Li et al. (2018) show B7S1-B7S1R signaling additionally regulates CD8⁺ T cell responses by working with the PD1-PDL1 checkpoint to block anti-tumor immunity.

Teaser

T cell checkpoint blockades can produce durable clinical responses, but only some patients and cancer types respond. In this issue of Immunity, Li et al. (2018) show B7S1-B7S1R signaling additionally regulates CD8⁺ T cell responses by working with the PD1-PDL1 checkpoint to block anti-tumor immunity.


https://ift.tt/2HIcLOp